Current Report · Items 3.02, 5.08, 8.01, 9.01 · 8-K
Vivos Inc
RDGLOTCEQUITYCurrent
Unregistered Sales of Equity Securities · Shareholder Director Nominations · Other Events
Item 3.02 Unregistered Sales of Equity Securities Issuance of Common Stock Pursuant to Offering Statement On October 30, 2026, Vivos Inc. (the “ Company ”) completed the sale and issuance of 12,500,000 shares of common stock, par value $0.001 per share (“ Common Stock ”), pursuant to its Regulation A+ offering being conducted on a “best efforts” basis under Regulation A of Section 3(6) of the Secu…
Company context
Current securities
Historical securities (6)
ADMDOTC · EQUITY · Historical · closed Oct 11, 2016ADMDOTC · EQUITY · Historical · closed Jan 2, 2018ADMDDOTC · EQUITY · Historical · closed Nov 7, 2016RDGLOTC · EQUITY · Historical · closed Jun 28, 2019RDGLOTC · EQUITY · Historical · closed Jun 28, 2019RDGLDOTC · EQUITY · Historical · closed Jul 29, 2019
Recent company filings
- 10-Q filingNov 12, 2026
- DEF 14A filingNov 9, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 8, 2026
- 8-K filingOct 5, 2026
- 10-Q filingAug 12, 2026
Disclosure sections
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item
3.02 Unregistered Sales of Equity Securities
Issuance
of Common Stock Pursuant to Offering Statement
On
October 30, 2026, Vivos Inc. (the “ Company ”) completed the sale and issuance of 12,500,000 shares of common stock,
par value $0.001 per share (“ Common Stock ”), pursuant to its Regulation A+ offering being conducted on a “best
efforts” basis under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “ Securities Act ”)
(the “ Offering ”). The Offering is being conducted pursuant to the Company’s offering statement on Form 1-A,
dated March 4, 2026 (“ Offering Statement ”), as filed with and qualified by the Securities and Exchange Commission
(the “ SEC ”) on March 5, 2026. The Offering resulted in gross proceeds to the Company of $1,000,000. Proceeds from
the sale of Common Stock in connection with the Offering will be used for general working capital purposes.
Please
see the Offering Statement for additional details regarding the Offering, including the terms of the Common Stock being offered.
The
issuance of the Common Stock was made in reliance upon an exemption from registration provided under Regulation A+ pursuant to Section
3(6) of the Securities Act.
Issuance
of Warrants
On
October 30, 2026, the Company completed the sale and issuance to certain accredited investors of warrants to purchase 25,000,000 shares
of its Common Stock (the “ Warrants ”), in consideration of an aggregate of $25,000, which warrants expire, if not previously
exercised, on December 31, 2030, and are exercisable for Common Stock at $.075 per share. The Warrants were issued pursuant to
Regulation D under the Securities Act.
Warrant
Exchange
On
October 30, 2026, the Company completed the issuance of 8,000,000 shares of Common Stock (the “ Exchange Shares ”) in
consideration for the cancellation of 8,000,000 warrants to purchase shares of Common Stock (the “ Warrant Exchange ”).
The Exchange Shares were issued in reliance on Sections 3(a)(9) and 4(2) of the Securities Act.
The
foregoing descriptions of the Warrant and Warrant Exchange Agreement do not purport to be complete and are qualified in their entirety
by the full text of the Form of Warrant and Form of Exchange Agreement filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this
Current Report on Form 8-K, and are incorporated by reference herein.
Item
5.08. Shareholder Director Nominations.
The
Company will host its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) virtually on December 9, 2026. The
Company’s Board of Directors has set a record date of November 2, 2026, entitling stockholders of record as of such date to notice
of and to vote at the 2026 Annual Meeting. As provided in Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “ Exchange
Act ”) (“ Rule 14a-8 ”), the Company is hereby providing the date by which shareholder proposals must be received
by the Company to be included in the proxy statement for the Annual Meeting. The Company will provide additional details regarding the
matters to be voted on and instructions for accessing the Annual Meeting in the Company’s proxy statement to be filed with the
SEC prior to the Annual Meeting.
To
be considered for inclusion in proxy materials for the Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 and intended
to be presented at the Annual Meeting must be received by the Company at 1030 N Center Parkway, Kennewick, WA 99336 no later than
the close of business on November 9, 2026. Any proposal received after such date will be considered untimely. All Rule 14a-8 proposals
must be in compliance with applicable laws and regulations in order to be considered for inclusion in the Company’s proxy materials
for the Annual Meeting. The public announcement of an adjournment or postponement of the date of the Annual Meeting will not commence
a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8.
Further,
to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees
must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by November 9, 2026.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events
See
Item 3.02 above.